| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2022―Oct―31 |
Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19 |
Shrikant Kulkarni, Varinder Kaur |
| 2 |
[GO] |
2022―May―31 |
Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry |
Sandro G Viveiros Rosa, Wilson C Santos |
| 3 |
[GO] |
2021―Jan―15 |
Repurposing drugs during the COVID-19 pandemic and beyond |
Srividya Ravi, Sammita Jadhav, Anuradha Vaidya, Ravindra Ghooi |
|
